At a Glance
Godavari Biorefineries (GBL), a Somaiya group company since 1939, plays in the bio-based chemicals and ethanol space with an integrated refinery spanning sugar, branded sugar, ethanol, bio-chemicals, and power. With a ₹1,534 Cr market cap and zero dividend yield, it’s currently limping with a low 5% sales CAGR over five years, negative ROE at -3.6%, and a volatile profit record. Debt levels have reduced, but interest coverage remains weak. The stock trades just about 2x book, but investors have to squint hard to spot growth and profitability shine here.
Introduction
Old-school meets modern bioeconomy? Godavari Biorefineries Ltd, a veteran in the Indian bio-refinery space, has a sprawling integrated setup and a unique product portfolio including India’s first bio-based Ethyl Vinyl Ether and being one of the only two global manufacturers of natural 1,3 Butylene Glycol.
But all this innovation hasn’t translated into sparkling financials lately. With slow sales growth and negative return on equity, it’s clear the company is navigating choppy waters amid sector challenges and competitive pressures.
Business Model (WTF Do They Even Do?)
GBL runs an integrated bio-refinery — starting from sugar manufacturing, then converting into ethanol and other bio-based chemicals, generating power as a byproduct. They also market branded products like sugar, turmeric, and salt under their “Jivana” brand in select states.
Their edge lies in bio-chemicals like Ethyl Vinyl Ether and specialty chemicals like MPO and natural Butylene Glycol — niche but capital intensive and technology-heavy lines.
Financials Overview
- Market Cap: ₹1,534 Cr
- Current Price: ₹298
- P/E: Not meaningful (due to losses)
- Book Value: ₹153
- ROCE: 5.8% (low)
- ROE: -3.65% (negative)
- Dividend Yield: 0%
Revenue stagnated at ₹1,870 Cr TTM, with a sluggish 5% sales CAGR over 5 years. Operating margins are volatile, swinging between losses and small profits. The net profit numbers tell a rollercoaster tale with sharp losses in some quarters offset by modest gains in others.
Valuation
At roughly 2x book value and zero dividend yield, the stock doesn’t scream value nor growth. The negative
